News and CommentGenomics

Alzheimer's Maverick Moves to Industry

See allHide authors and affiliations

Science  27 Jun 1997:
Vol. 276, Issue 5321, pp. 1962
DOI: 10.1126/science.276.5321.1962

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

Since 1994, the British drug company Glaxo Wellcome has been buying bits and pieces of U.S. biotech firms as part of a push into genetics. On 17 June, the company announced a surprising choice to direct its $47 million genetics empire: Allen Roses of Duke University, a prominent neuroscientist and controversial Alzheimer's disease researcher.